Lexaria Book Value Per Share vs Price To Sales Ratio Analysis

LEXXW Stock  USD 0.80  0.05  6.67%   
Lexaria Bioscience financial indicator trend analysis is infinitely more than just investigating Lexaria Bioscience Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lexaria Bioscience Corp is a good investment. Please check the relationship between Lexaria Bioscience Book Value Per Share and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Book Value Per Share vs Price To Sales Ratio

Book Value Per Share vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lexaria Bioscience Corp Book Value Per Share account and Price To Sales Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Lexaria Bioscience's Book Value Per Share and Price To Sales Ratio is -0.4. Overlapping area represents the amount of variation of Book Value Per Share that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Lexaria Bioscience Corp, assuming nothing else is changed. The correlation between historical values of Lexaria Bioscience's Book Value Per Share and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Book Value Per Share of Lexaria Bioscience Corp are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Book Value Per Share i.e., Lexaria Bioscience's Book Value Per Share and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.4
Relationship DirectionNegative 
Relationship StrengthVery Weak

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Lexaria Bioscience Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Lexaria Bioscience sales, a figure that is much harder to manipulate than other Lexaria Bioscience Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.
Most indicators from Lexaria Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lexaria Bioscience Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
At this time, Lexaria Bioscience's Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 395.77 in 2024, whereas Selling General Administrative is likely to drop slightly above 2.5 M in 2024.
 2021 2023 2024 (projected)
Other Operating Expenses7.6M6.2M3.2M
Interest Expense114.3K102.9K125.2K

Lexaria Bioscience fundamental ratios Correlations

0.460.290.990.05-0.9-0.660.510.950.220.950.530.120.360.620.760.310.230.95-0.55-0.19-0.540.49-0.19-0.550.32
0.460.420.42-0.18-0.43-0.70.970.450.00.420.550.290.740.90.710.450.010.48-0.31-0.270.090.0-0.29-0.50.73
0.290.420.140.80.12-0.070.510.020.870.01-0.220.240.430.260.111.00.880.03-0.430.420.180.130.410.130.27
0.990.420.14-0.09-0.95-0.690.460.980.080.990.590.090.310.610.780.160.080.98-0.51-0.28-0.60.46-0.28-0.60.3
0.05-0.180.8-0.090.370.31-0.06-0.230.97-0.23-0.550.080.03-0.29-0.280.780.97-0.25-0.270.650.110.20.650.41-0.16
-0.9-0.430.12-0.950.370.68-0.43-0.990.22-0.99-0.68-0.05-0.23-0.62-0.760.10.21-0.990.380.420.55-0.360.420.67-0.34
-0.66-0.7-0.07-0.690.310.68-0.68-0.680.1-0.66-0.88-0.17-0.66-0.87-0.99-0.120.11-0.710.290.570.48-0.390.590.66-0.33
0.510.970.510.46-0.06-0.43-0.680.470.120.440.480.370.760.910.70.540.130.5-0.4-0.180.07-0.02-0.2-0.50.76
0.950.450.020.98-0.23-0.99-0.680.47-0.071.00.630.070.280.630.770.04-0.071.0-0.45-0.34-0.550.39-0.34-0.640.35
0.220.00.870.080.970.220.10.12-0.07-0.07-0.370.130.21-0.08-0.060.860.99-0.08-0.370.560.020.280.560.27-0.05
0.950.420.010.99-0.23-0.99-0.660.441.0-0.070.620.070.260.610.760.03-0.071.0-0.45-0.34-0.570.4-0.34-0.630.33
0.530.55-0.220.59-0.55-0.68-0.880.480.63-0.370.62-0.010.510.680.86-0.18-0.410.660.13-0.77-0.30.46-0.8-0.550.14
0.120.290.240.090.08-0.05-0.170.370.070.130.07-0.010.250.340.180.240.150.09-0.3-0.160.01-0.32-0.140.10.15
0.360.740.430.310.03-0.23-0.660.760.280.210.260.510.250.690.650.490.210.32-0.18-0.24-0.010.2-0.28-0.360.38
0.620.90.260.61-0.29-0.62-0.870.910.63-0.080.610.680.340.690.880.3-0.070.66-0.45-0.41-0.240.05-0.42-0.640.64
0.760.710.110.78-0.28-0.76-0.990.70.77-0.060.760.860.180.650.880.15-0.070.8-0.35-0.53-0.50.41-0.55-0.680.36
0.310.451.00.160.780.1-0.120.540.040.860.03-0.180.240.490.30.150.870.05-0.440.390.160.150.390.10.28
0.230.010.880.080.970.210.110.13-0.070.99-0.07-0.410.150.21-0.07-0.070.87-0.07-0.430.58-0.010.220.580.24-0.03
0.950.480.030.98-0.25-0.99-0.710.51.0-0.081.00.660.090.320.660.80.05-0.07-0.45-0.37-0.550.41-0.37-0.640.35
-0.55-0.31-0.43-0.51-0.270.380.29-0.4-0.45-0.37-0.450.13-0.3-0.18-0.45-0.35-0.44-0.43-0.45-0.290.590.15-0.320.44-0.42
-0.19-0.270.42-0.280.650.420.57-0.18-0.340.56-0.34-0.77-0.16-0.24-0.41-0.530.390.58-0.37-0.290.22-0.181.00.060.26
-0.540.090.18-0.60.110.550.480.07-0.550.02-0.57-0.30.01-0.01-0.24-0.50.16-0.01-0.550.590.22-0.260.20.480.18
0.490.00.130.460.2-0.36-0.39-0.020.390.280.40.46-0.320.20.050.410.150.220.410.15-0.18-0.26-0.2-0.06-0.26
-0.19-0.290.41-0.280.650.420.59-0.2-0.340.56-0.34-0.8-0.14-0.28-0.42-0.550.390.58-0.37-0.321.00.2-0.20.090.24
-0.55-0.50.13-0.60.410.670.66-0.5-0.640.27-0.63-0.550.1-0.36-0.64-0.680.10.24-0.640.440.060.48-0.060.09-0.64
0.320.730.270.3-0.16-0.34-0.330.760.35-0.050.330.140.150.380.640.360.28-0.030.35-0.420.260.18-0.260.24-0.64
Click cells to compare fundamentals

Lexaria Bioscience Account Relationship Matchups

Lexaria Bioscience fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets2.8M13.3M7.8M3.1M8.9M9.3M
Other Current Liab96.7K45K51.7K239.9K1.1M1.1M
Total Current Liabilities225.9K153.3K194.0K267.7K1.1M1.2M
Total Stockholder Equity2.5M13.3M7.9M3.0M8.0M8.4M
Property Plant And Equipment Net610.3K459.3K367.9K421.6K389.6K370.1K
Net Debt(1.1M)(10.8M)(5.8M)(1.2M)(6.4M)(6.0M)
Retained Earnings(27.8M)(31.8M)(39.1M)(45.8M)(51.6M)(49.0M)
Accounts Payable45.1K59.9K25.8K225.0K1.1M1.1M
Cash1.3M10.9M5.8M1.4M6.5M6.8M
Non Current Assets Total902.3K823.9K856.4K884.2K969.8K1.3M
Cash And Short Term Investments1.3M11.8M6.2M1.5M6.6M6.9M
Common Stock Shares Outstanding2.8M4.4M5.9M6.6M12.4M13.0M
Liabilities And Stockholders Equity2.8M13.3M7.8M3.1M8.9M9.3M
Non Current Liabilities Total120.1K50.0K7.4K136.2K109.3K209.8K
Other Current Assets182.1K319.3K576.8K546.8K1.2M1.2M
Other Stockholder Equity30.3M45.1M47.0M48.8M59.6M62.6M
Total Liab346.0K203.3K201.4K403.9K1.2M1.3M
Property Plant And Equipment Gross483.4K773.2K747.9K896.8K807.1K1.4M
Total Current Assets1.9M12.4M7.0M2.2M7.9M8.3M
Common Stock90.0K5.7K6.0K8.1K9.3K8.8K
Net Receivables313.9K342.4K201.8K175.2K154.5K166.2K
Inventory116.9K29.6K38.4K1.00.90.86
Non Currrent Assets Other(902.3K)(823.9K)(856.4K)(884.2K)63.6K66.8K
Intangible Assets292K364.6K488.5K462.6K516.7K295.9K
Net Invested Capital2.6M13.3M7.9M3.0M3.5M5.4M
Net Working Capital1.7M12.3M6.8M1.9M2.2M2.1M
Short Term Investments19.3K833.8K347.3K125.6K55.8K53.0K
Capital Stock90.0K5.7K6.0K8.1K7.3K6.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.